Eli Lilly has started selling Foundayo, its once-a-day weight loss pill, in the United Kingdom. This is the first European market for a drug that the company hopes will follow Mounjaro and Zepbound, the two products that now bring in almost 15 billion USD every quarter. The LLY stock forecast below sets out what the […]
All posts
16 min
On Monday, June 8, LLY shares opened with a 2.5% gap up following the release of full Phase 3 clinical trial results for Retatrutide. This experimental weight loss drug could become Eli Lilly's next major product after Mounjaro and Zepbound — and the data are significantly stronger than anything seen from rivals. In Brief Average […]